Vintage receives warning letter
Executive Summary
Vintage Pharmaceuticals has failed to fulfill post-marketing adverse event reporting commitments, a May 26 FDA 1warning letter states. "Our inspection revealed that your firm had never submitted an [adverse drug experience] to FDA" for any ANDA, the letter states. The company said it submitted a response to FDA and views the matter as closed...